BioSpace News Archive

The ASH Research Collaborative (ASH RC) has announced the first 10 clinical research consortia to join the ASH RC Sickle Cell Disease Clinical Trials Network.

Calidi Biotherapeutics, Inc., together with the University of Chicago and City of Hope, a world renowned NCI-Designated Comprehensive Cancer Center, based in Duarte, California, have entered into an exclusive worldwide licensing agreement for patents covering cutting edge therapies using an oncolytic adenovirus in combination with a clinical grade allogeneic neural stem cell line.

SOF4 is a gas that was discovered over a hundred years ago but is rarely used because it is difficult to prepare and highly reactive.

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced financial results for the second quarter and first half of 2021 and provided business update.

Pfizer Inc. and BioNTech SE announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration to support the evaluation of a third, or booster dose of the companies’ COVID-19 vaccine for future licensure.

Eurofins Transplant Genomics announces the formation of their 2021-2022 Scientific Advisory Board.

Ligand Pharmaceuticals Incorporated announces that its partner Travere Therapeutics, Inc. today announced positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan, an investigational product candidate for the treatment of IgA nephropathy (IgAN).

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today reported its financial results for the second quarter ended June 30, 2021 and provided an update on the company’s operations.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Jim Kelly as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, and Nasir Egal, Ph.D. as Senior Vice President, Quality Assurance.

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a specific billing Level II Healthcare Common Procedure Coding System (HCPCS) code for PEPAXTO®.